225 related articles for article (PubMed ID: 28744948)
1. A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
Sharpe B; Alghezi DA; Cattermole C; Beresford M; Bowen R; Mitchard J; Chalmers AD
Prostate; 2017 May; 77(13):1312-1324. PubMed ID: 28744948
[TBL] [Abstract][Full Text] [Related]
2. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
3. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
4. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.
Hägglöf C; Hammarsten P; Josefsson A; Stattin P; Paulsson J; Bergh A; Ostman A
PLoS One; 2010 May; 5(5):e10747. PubMed ID: 20505768
[TBL] [Abstract][Full Text] [Related]
5. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer.
Kind S; Jaretzke A; Büscheck F; Möller K; Dum D; Höflmayer D; Hinsch A; Weidemann S; Fraune C; Möller-Koop C; Hube-Magg C; Simon R; Wilczak W; Lebok P; Witzel I; Müller V; Schmalfeldt B; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Krech T; Krech RH; von der Assen A; Bawahab AA; Burandt E
Mol Carcinog; 2019 Dec; 58(12):2306-2315. PubMed ID: 31545001
[TBL] [Abstract][Full Text] [Related]
6. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.
Szarvas T; Reis H; Kramer G; Shariat SF; Vom Dorp F; Tschirdewahn S; Schmid KW; Kovalszky I; Rübben H
Hum Pathol; 2014 Apr; 45(4):674-82. PubMed ID: 24656090
[TBL] [Abstract][Full Text] [Related]
7. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.
Wu JP; Huang WB; Zhou H; Xu LW; Zhao JH; Zhu JG; Su JH; Sun HB
Asian J Androl; 2014; 16(5):710-4. PubMed ID: 24875819
[TBL] [Abstract][Full Text] [Related]
8. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
Zellweger T; Ninck C; Mirlacher M; Annefeld M; Glass AG; Gasser TC; Mihatsch MJ; Gelmann EP; Bubendorf L
Prostate; 2003 Apr; 55(1):20-9. PubMed ID: 12640657
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression.
Brimo F; Vollmer RT; Friszt M; Corcos J; Bismar TA
BJU Int; 2010 Aug; 106(3):418-23. PubMed ID: 20002675
[TBL] [Abstract][Full Text] [Related]
10. Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence.
Kind S; Kluth M; Hube-Magg C; Möller K; Makrypidi-Fraune G; Lutz F; Lennartz M; Rico SD; Schlomm T; Heinzer H; Höflmayer D; Weidemann S; Uhlig R; Huland H; Graefen M; Bernreuther C; Tsourlakis MC; Minner S; Dum D; Hinsch A; Lübke AM; Simon R; Sauter G; Marx A; Polonski A
Biomed Res Int; 2020; 2020():5845374. PubMed ID: 33195694
[TBL] [Abstract][Full Text] [Related]
11. Syndecan Family Gene and Protein Expression and Their Prognostic Values for Prostate Cancer.
Santos NJ; Barquilha CN; Barbosa IC; Macedo RT; Lima FO; Justulin LA; Barbosa GO; Carvalho HF; Felisbino SL
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445387
[TBL] [Abstract][Full Text] [Related]
12. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Expression of Syndecan-1 in Cervical Cancers.
Karászi K; Vigh R; Máthé M; Fullár A; Oláh L; Füle T; Papp Z; Kovalszky I
Pathol Oncol Res; 2020 Oct; 26(4):2255-2264. PubMed ID: 32388727
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J; Kallajoki M; Kujala I; Matikainen MT; Alanen K; Jalkanen M; Salmivirta M
APMIS; 2004 Feb; 112(2):89-97. PubMed ID: 15056224
[TBL] [Abstract][Full Text] [Related]
15. Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.
Nordby Y; Andersen S; Richardsen E; Ness N; Al-Saad S; Melbø-Jørgensen C; Patel HR; Dønnem T; Busund LT; Bremnes RM
Prostate; 2015 Nov; 75(15):1682-93. PubMed ID: 26268996
[TBL] [Abstract][Full Text] [Related]
16. Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas.
Máthé M; Suba Z; Németh Z; Tátrai P; Füle T; Borgulya G; Barabás J; Kovalszky I
Oral Oncol; 2006 May; 42(5):493-500. PubMed ID: 16364677
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
18. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma.
Jia X; Sun Y; Wang B
IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296
[TBL] [Abstract][Full Text] [Related]
19. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
20. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
